Global Protein Engineering and Expression Market

1. Summary

The Global Protein Engineering and Expression Market was valued at $4.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 12.5% CAGR, to an estimated market size of $8.7 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global Protein Engineering and Expression market encompasses the technologies, instruments, reagents, and services used to design, modify, and synthesize recombinant proteins. This includes the entire workflow from computational design and genetic manipulation to the production of proteins using various host systems such as mammalian, bacterial, and yeast cells for applications in therapeutics, diagnostics, and industrial biotechnology.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Protein Engineering and Expression Market in the period 2025-30:

• The integration of Artificial Intelligence and machine learning is revolutionizing protein design by shifting from trial-and-error wet-lab experiments to predictive modeling of protein structures.
• Rising demand for biologics and monoclonal antibodies to treat chronic diseases like cancer and autoimmune disorders is a primary driver for advanced expression systems.
• The adoption of Cell-Free Protein Synthesis (CFPS) is increasing as it allows for rapid production and the synthesis of proteins that are otherwise toxic to living host cells.
• Advancements in CRISPR-Cas9 and other gene-editing technologies are enabling more precise and efficient modification of protein-coding sequences.
• There is a significant shift toward outsourcing protein engineering and expression tasks to specialized CROs and CDMOs to reduce capital expenditure and access expert technical capabilities.
• The growth of personalized medicine is fueling the need for custom-engineered proteins tailored to individual genetic profiles and specific therapeutic targets.
• Technological focus is shifting toward improving post-translational modifications in mammalian systems to ensure the efficacy and safety of complex human-like proteins.
• High capital costs and the requirement for specialized laboratory infrastructure remain significant barriers to entry for smaller biotechnology firms.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: